Amylyx Pharmaceuticals, Inc. (AMLX)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Amylyx Pharmaceuticals, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Amylyx Pharmaceuticals, Inc. (AMLX) has returned 15.07% so far this year and 292.66% over the past 12 months.

Based on dividend-adjusted daily data since Jan 7, 2022, AMLX's average daily return is +0.20%, while the average monthly return is +4.99%. At this rate, your investment would double in approximately 1.2 years.

Historically, 57% of months were positive and 43% were negative. The best month was Jun 2022 with a return of +116.7%, while the worst month was Mar 2024 at -84.9%. The longest winning streak lasted 9 consecutive months, and the longest losing streak was 5 months.

On a daily basis, AMLX closed higher 50% of trading days. The best single day was Sep 8, 2022 with a return of +51.0%, while the worst single day was Mar 8, 2024 at -82.3%.

Amylyx Pharmaceuticals, Inc. has an annualized alpha of 46.82%, beta of 1.19, and R² of 0.05 versus S&P 500 Index. Calculated based on daily prices since January 10, 2022.

• This stock tended to rise when S&P 500 Index fell (downside capture of -54.56%), but participation in market rallies was also limited (-36.69%) — a profile typical of counter-cyclical assets.
• R² of 0.05 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

AMLX ranks 97 for risk / return — in the top 97% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for Amylyx Pharmaceuticals, Inc. (AMLX) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Amylyx Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Amylyx Pharmaceuticals, Inc. was 96.04%, occurring on Jun 18, 2024. The portfolio has not yet recovered.

The current Amylyx Pharmaceuticals, Inc. drawdown is 66.04%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Amylyx Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Amylyx Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.